New Research Announced into Alzheimer's Disease


Neuro Bio Announcement

Neuro-Bio Ltd has made an exciting new announcement this week. The UK-based early stage biopharmaceutical company specialising inneurodegenerative diseases, announced it has received the funding needed for them to carry out their research. Thanks to Kairos Ventures, they received Series A funding of $3.2 million. This is to continue developing a diagnostic tool for early detection of Alzheimer’s and to discover new drugs targeting the disease. Neuro-Bio has been pioneering a novel approach to Alzheimer’s disease and related neurodegenerative disorders since 2013 and this support will enable them to take their work farther than ever best and change millions of lives around the world.

The innovative technology is the result of over 40 years of basic research by Baroness Susan Greenfield and her team, initially at Oxford University, who found a previously unidentified mechanism underlying the continuing cycle of cell death that characterises the neuro-degenerative process.

Susan has been researching whether activation of this brain mechanism could be halted by pharmaceutical intervention and how these changes are reflected in a biomarker present in blood. The new investment will allow Neuro-Bio to develop the biomarker into a diagnostic tool and to make substantive progress towards identifying a lead compound with promising therapeutic potential in Alzheimer’s disease.

Neuro-Bio’s Founder and CEO, Baroness Susan Greenfield commented “We are delighted to have secured this Series A investment to support the continued growth of our company from start-up to small enterprise. The investment from Kairos is a recognition of our fresh approach as well as the expertise of our team: this investment will increase the possibility of discovery of a novel disruptive treatment that is much needed to improve outcomes for patients with Alzheimer’s disease''.

Professor Margaret Esiri, Neuropathologist at the Nuffield Department of Clinical Sciences said, “Neuro-Bio's approach to the problem of Alzheimer's disease is novel and scientifically well-founded. It is a good example of the new thinking that is urgently needed in this field.”
The new research could benefit many lives of people living with the disease. As the population ages, research has to be done on diseases that affect older people more.

For further information about , you can watch this video about Susan Greenfield here:

You Might Also Like